Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study
In brief
Osimertinib cuts time to next therapy by about 87% in unresectable stage III EGFR-mutated lung cancer
In the LAURA trial, patients receiving osimertinib after chemoradiotherapy started their first subsequent treatment far later than those on placebo, with an 87% lower risk of needing another systemic therapy. Benefits also extended to second-line progression-free survival and time to second subsequent treatment, and a trend toward overall-survival improvement was observed.
- Journal
- Clinical cancer research : an official journal of the American Association for Cancer Research (Q1)
- Published
- 9 September 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Mustafa Özgüroğlu, Myung-Ju Ahn, Xiaorong Dong, James Chih-Hsin Yang, Satoshi Oizumi, Koichi Goto, et al.
- PMID
- 42714840
- DOI
- 10.1158/1078-0432.CCR-25-4523
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (paper of the day, 12 September 2026): Osimertinib after chemoradiotherapy in unresectable stage III EGFR‑mutated NSCLC
Abstract
INTRODUCTION: In the phase III LAURA study, osimertinib demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without disease progression during/after chemoradiotherapy. We report pre-specified post-progression outcomes, subsequent treatments and a second interim analysis of overall survival (OS). METHODS: Patients were randomized 2:1 to receive osimertinib or placebo until progression (blinded independent central review) or discontinuation. Open-label osimertinib was offered post-progression. Secondary endpoints included time to first and second subsequent treatment (TFST and TSST), second PFS (PFS2) and OS. RESULTS: At primary data cutoff (January 5, 2024), TFST (hazard ratio [HR], 0.13; 95% CI, 0.08-0.21), PFS2 (0.62; 0.35-1.08) and TSST (0.51; 0.28-0.91) were improved with osimertinib versus placebo. As reported previously, 63/143 (44%) and 66/73 (90%) patients had discontinued randomized osimertinib and placebo treatment, respectively. The most common first subsequent systemic treatment was an EGFR-tyrosine kinase inhibitor in the osimertinib and placebo arms (22/63 [35%] and 56/66 [85%], respectively), primarily osimertinib (14/63 [22%] and 50/66 [76%]). At the second interim OS analysis (data cutoff: November 29, 2024), there was a trend towards OS benefit with osimertinib versus placebo (HR, 0.67; 95% CI, 0.40-1.14; 31% maturity). CONCLUSIONS: Osimertinib demonstrated clinically meaningful improvements versus placebo in TFST, PFS2 and TSST, and a trend towards OS benefit. These data indicate that clinical benefit with osimertinib was preserved beyond first progression, supporting long-term benefits of osimertinib for unresectable stage III EGFR-mutated NSCLC without progression during/after definitive chemoradiotherapy.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.